ClinicalTrials.gg
Active, not recruitingNCT05785767Updated Jul 2, 2026

A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)

A Phase 2/3 interventional study of fianlimab and cemiplimab in Advanced Non-Small Cell Lung Cancer, sponsored by Regeneron Pharmaceuticals. Active, not recruiting at 106 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-02.

Sponsored by Regeneron Pharmaceuticals · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
149
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies in Carcinoma, Non-Small-Cell Lung by Regeneron Pharmaceuticals — 2 open to participants now, 11 under way, 2 of them phase 3. Carcinoma, Non-Small-Cell Lung · Regeneron Pharmaceuticals.

Enrollment
8th of 18
149 · median 86
Started
2023
with 2 others
Phase 2/3
2 of 21
none open now
Primary completion
2027-09
later than 4 of 10 live
Registered
14th of 21
by date

Among the 21 studies in Carcinoma, Non-Small-Cell Lung by Regeneron Pharmaceuticals, this one is the 8th largest by enrollment of the 18 interventional ones that give a count, is one of 3 that started in 2023, is one of 2 in phase 2/3, reaches primary completion later than 4 of the 10 other live ones, and was the 14th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

2 of the 21 studies in Carcinoma, Non-Small-Cell Lung by Regeneron Pharmaceuticals are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Carcinoma, Non-Small-Cell Lung by Regeneron Pharmaceuticals, or all of them as a file.
02

Study summary

This study is researching an experimental drug called fianlimab (also called REGN3767), combined with a medication called cemiplimab (also called REGN2810), individually called a "study drug" or collectively called "study drugs". The study is focused on patients who have advanced non-small cell lung cancer (NSCLC).

The aim of the study is to see how effective the combination of fianlimab and cemiplimab is in treating advanced NSCLC, in comparison with cemiplimab by itself.

The study is looking at several other research questions, including:

  • What side effects may happen from taking the study drugs
  • How much study drug is in your blood at different times
  • Whether the body makes antibodies against the study drugs (which could make the drug less effective or could lead to side effects)
  • How administering the study drugs might improve your quality of life
Read the detailed description

Phase 3 was not initiated and no participants were enrolled.

03

Conditions studied

  • Advanced Non-Small Cell Lung Cancer

Keywords

  • Treatment naïve
  • NSCLC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Patients with non-squamous or squamous histology NSCLC with stage IIIB or stage IIIC disease who are not candidates for surgical resection or definitive chemoradiation per investigator assessment or stage IV ( disease), who received no prior systemic treatment for recurrent or metastatic NSCLC.
  2. Availability of an archival or on-study formalin-fixed, paraffin-embedded (FFPE) tumor tissue sample, without intervening therapy between collection and screening as described in the protocol
  3. For enrollment in phase 2, patients should have levels ≥ 50%, as determined by a College of American Pathologists (CAP)/Clinical Laboratory Improvement Amendments (CLIA) (or equivalently licensed, according to local regulations) accredited laboratory, as described in the protocol
  4. At least 1 radiographically by computed tomography (CT) or magnetic resonance imaging (MRI) per version 1.1 (RECIST 1.1) criteria. Target lesions may be located in a previously irradiated field if there is documented (radiographic) disease progression in that site.
  5. (ECOG) performance status of ≤1.
  6. Adequate organ and bone marrow function, as described in the protocol.

Key Exclusion Criteria:

  1. Patients who have never smoked, defined as smoking ≤100 cigarettes in a lifetime.
  2. Active or untreated or spinal cord compression. Patients are eligible if central nervous system (CNS) metastases are adequately treated, and patients have neurologically returned to baseline (except for residual signs or symptoms related to the CNS treatment) for at least 2 weeks prior to enrollment. Patients must be off ( doses of) therapy.
  3. Patients with tumors tested positive for actionable epidermal growth factor receptor (EGFR) gene mutations, anaplastic lymphoma kinase (ALK) gene translocations, or c-ros oncogene 1 (ROS1) fusions, as described in the protocol.
  4. Encephalitis, meningitis, or uncontrolled seizures in the year prior to enrollment.
  5. History of interstitial lung disease (eg, idiopathic pulmonary fibrosis or organizing pneumonia), of active, noninfectious pneumonitis that required immune-suppressive doses of glucocorticoids to assist with management, or of pneumonitis within the last 5 years. A history of radiation pneumonitis in the radiation field is permitted as long as pneumonitis resolved ≥6 months prior to enrollment.
  6. Known primary immunodeficiencies, either cellular (eg, DiGeorge syndrome, T-cell-negative severe combined immunodeficiency [SCID]) or combined T- and B-cell immunodeficiencies (eg, T- and B-cell negative SCID, Wiskott Aldrich syndrome, ataxia telangiectasia, common variable immunodeficiency).
  7. Ongoing or recent (within 2 years) evidence of significant disease that required treatment with systemic immunosuppressive treatments, which may suggest risk of immune-mediated treatment-emergent adverse events (imTEAEs). Patients with uncontrolled type 1 diabetes mellitus or with uncontrolled adrenal insufficiency are excluded. The following are not exclusionary: vitiligo, childhood asthma that has resolved, residual hypothyroidism that required only hormone replacement, or psoriasis that does not require systemic treatment.
  8. Patients with a condition requiring corticosteroid therapy (>10 mg prednisone/day or equivalent) within 14 days of randomization. Physiologic replacement doses are allowed even if they are >10 mg of prednisone/day or equivalent, as long as they are not being administered for immunosuppressive intent. Patients with systemic immune suppression within the last 3 months before trial enrollment are excluded. Inhaled or topical steroids are permitted, provided that they are not for treatment of an autoimmune disorder.
  9. Patients who have received prior systemic therapies are excluded with the exception of the following:

    1. Adjuvant or platinum-based doublet chemotherapy (after surgery and/or radiation therapy) if recurrent or metastatic disease develops more than 6 months after completing therapy as long as toxicities have resolved to grade ≤1 or baseline with the exception of alopecia and peripheral neuropathy.
    2. Anti-PD-(L) 1 with or without LAG-3 as an adjuvant or neoadjuvant therapy as long as the last dose is >12 months prior to enrollment.
    3. Prior exposure to other immunomodulatory or vaccine therapies as an adjuvant or neoadjuvant therapy, Cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4) antibodies as long as the last dose is >6 months prior to enrollment. Immune-mediated AEs must be resolved to CTCAE grade ≤1 or baseline by the time of enrollment. Endocrine immune-mediated AEs controlled with hormonal or other non-immunosuppressive therapies without resolution prior to enrollment are allowed.

Note: Other protocol-defined Inclusion/ Exclusion Criteria apply.

Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
149 participants (actual)

Study arms

  • Experimental
    A: fianlimab+cemiplimab

    Phase 2: fianlimab (HD)

    Drug: fianlimab · Drug: cemiplimab

  • Experimental
    B: fianlimab+cemiplimab

    Phase 2: fianlimab (LD)

    Drug: fianlimab · Drug: cemiplimab

  • Experimental
    C: cemiplimab monotherapy+placebo

    Phase 2

    Drug: cemiplimab · Drug: Placebo

Interventions

  • Administered per the protocol

    Also known as: REGN3767

  • Administered per the protocol

    Also known as: REGN2810, Libtayo

  • DrugPlacebo

    Administered per the protocol

06

What researchers measure

Primary outcomes

  1. Objective response rate (ORR) as assessed by blinded independent central review (BICR), using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)

    Proportion of patients with a best overall response of confirmed complete response (CR) or partial response (PR)

    Time frame: Up to 136 weeks

Secondary outcomes

  1. Incidence of treatment-emergent adverse events (TEAEs)

    Time frame: Up to 136 weeks

  2. Incidence of treatment-related TEAEs

    Time frame: Up to 136 weeks

  3. Incidence of serious adverse events (SAEs)

    Time frame: Up to 136 weeks

  4. Incidence of adverse events of special interest (AESIs)

    Time frame: Up to 136 weeks

  5. Incidence of immune-mediated adverse events (imAEs)

    Time frame: Up to 136 weeks

  6. Occurrence of interruption of study drug(s) due to TEAEs

    Time frame: Up to 136 weeks

  7. Occurrence of discontinuation of study drug(s) due to TEAEs

    Time frame: Up to 136 weeks

  8. Occurrence of interruption of study drug(s) due to AESIs

    Time frame: Up to 136 weeks

  9. Occurrence of discontinuation of study drug(s) due to AESIs

    Time frame: Up to 136 weeks

  10. Occurrence of interruption of study drug(s) due to imAEs

    Time frame: Up to 136 weeks

  11. Occurrence of discontinuation of study drug(s) due to imAEs

    Time frame: Up to 136 weeks

  12. Incidence of deaths due to TEAE

    Time frame: Up to 136 weeks

  13. Incidence of grade 3 to 4 laboratory abnormalities

    ≥ grade 3 per National Cancer Institute-Common Terminology Criteria for Adverse Events \[NCI-CTCAE v5.0\]

    Time frame: Up to 136 weeks

  14. ORR by investigator assessment, using RECIST 1.1

    Time frame: Up to 136 weeks

  15. Disease control rate (DCR) by BICR

    Time frame: Up to 136 weeks

  16. DCR by investigator assessment

    Time frame: Up to 136 weeks

  17. Time to tumor response (TTR) by BICR

    Time frame: Up to 136 weeks

  18. TTR by investigator assessment

    Time frame: Up to 136 weeks

  19. Duration of response (DOR) by BICR

    Time frame: Up to 5 years

  20. DOR by investigator assessment

    Time frame: Up to 5 years

  21. Progression free survival (PFS) by BICR

    Time frame: Up to 5 years

  22. PFS by investigator assessment

    Time frame: Up to 5 years

  23. Overall survival (OS)

    Time frame: Up to 5 years

  24. Change from baseline in patient-reported Global Health Status/Quality of Life (GHS/QoL) per European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30)

    EORTC-QLQ-C30 is a 30-item subject self-report questionnaire composed of both multi-item and single scales, including a GHS/QoL scale. Participants rate items on a four-point scale, with 1 as "not at all" and 4 as "very much." A change of 5 - 10 points is considered a small change. A change of 10 - 20 points is considered a moderate change.

    Time frame: Up to 5 years

  25. Change from baseline in patient-reported physical functioning per EORTC QLQ-C30

    Time frame: Up to 5 years

  26. Change from baseline in patient-reported chest pain per European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer (EORTC QLQ-LC13)

    EORTC QLQ-LC 13 is a lung cancer specific module developed to assess lung cancer-associated symptoms and treatment-related side effects among lung cancer patients

    Time frame: Up to 5 years

  27. Change from baseline in patient-reported dyspnea per EORTC QLQ-LC13

    Time frame: Up to 5 years

  28. Change from baseline in patient-reported cough per EORTC QLQ-LC13

    Time frame: Up to 5 years

  29. Time until definitive deterioration in patient-reported global health status/QoL per EORTC QLQ-C30

    Time frame: Up to 5 years

  30. Time until definitive deterioration in patient-reported physical functioning per EORTC QLQ-C30

    Time frame: Up to 5 years

  31. Time until definitive deterioration in patient-reported chest pain per EORTC QLQ-LC13

    Time frame: Up to 5 years

  32. Time until definitive deterioration in patient-reported dyspnea per EORTC QLQ-LC13

    Time frame: Up to 5 years

  33. Time until definitive deterioration in patient-reported cough per EORTC QLQ-LC13

    Time frame: Up to 5 years

  34. Time until definitive deterioration in patient-reported composite of chest pain, dyspnea and cough per EORTC QLQ-LC13

    Time frame: Up to 5 years

  35. Change from baseline in patient-reported general health status per EuroQoL-5 Dimensions, 5-level Questionnaire-Visual Analogue Score (EQ-5D-5L VAS)

    The EQ-5D-5L VAS records the respondent's self-rated health on a 10 centimeter (cm) vertical, visual analogue scale. It is rated by the respondent on a scale 0 to 100, with 0 being "the worst health you can imagine" and 100 being "the best health you can imagine".

    Time frame: Up to 5 years

  36. Change from baseline in patient-reported severity with usual or daily activities due to fatigue per the Patient Reported Outcomes for Common Terminology Criteria for Adverse Events (PRO-CTCAE).

    PRO-CTCAE questionnaire assesses side effect symptoms in cancer clinical trials using a PRO-CTCAE score. The PRO-CTCAE includes an item library of 124 items representing 78 symptomatic toxicities drawn from the CTCAE.

    Time frame: Up to 5 years

  37. Change from baseline in patient-reported interference with usual or daily activities due to fatigue per the Patient Reported Outcomes for Common Terminology Criteria for Adverse Events (PRO-CTCAE).

    Time frame: Up to 5 years

  38. Concentrations of cemiplimab in serum

    Time frame: Up to 136 weeks

  39. Concentrations of fianlimab in serum

    Time frame: Up to 136 weeks

  40. Immunogenicity, as measured by anti-drug antibodies (ADA) to fianlimab

    Time frame: Up to 136 weeks

  41. Immunogenicity, as measured by ADA to cemiplimab

    Time frame: Up to 136 weeks

  42. Immunogenicity, as measured by neutralizing antibodies (NAb) to fianlimab

    Time frame: Up to 136 weeks

  43. Immunogenicity, as measured by NAb to cemiplimab

    Time frame: Up to 136 weeks

07

Study locations

106 sites

Showing the first 100 of 106 sites across 11 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy.

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2023 (actual). Primary completion is estimated for Sep 2027, 50 months after the start.

Of 56 phase 2/3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 40. This study's planned 50 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2023
First posted
Mar 27, 2023
StartActual
Jun 30, 2023
Primary completionEst.
Sep 28, 2027
CompletionEst.
Sep 28, 2027
Last update
Jul 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05785767
Responsible party
Sponsor
First posted
Mar 27, 2023
Start date
Jun 30, 2023
Primary completion
Sep 28, 2027 (estimated)
Completion
Sep 28, 2027 (estimated)
Last update
Jul 2, 2026

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fianlimab

Start the discussion